Evaluation of changes in skin and joint outcomes and associated treatment changes in psoriatic arthritis (PsA): Experience from the corrona PsA/SpA registry

Philip J. Mease, Carol J. Etzel, William J. Huster, April W. Armstrong, Talia M. Muram, Jeffrey Lisse, Sabrina Rebello, Rhiannon Dodge, Mwangi J. Murage, Jeffrey D. Greenberg, William N. Malatestinic

Research output: Contribution to journalArticlepeer-review

Abstract

Objective. To characterize skin severity and joint activity outcomes and associated treatment changes in patients with psoriatic arthritis (PsA) through 12 months of follow-up after enrollment in the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry. Methods. Patients ≥ 18 years of age with a diagnosis of PsA and a history of psoriasis between March 21, 2013, and September 30, 2016, were enrolled (n = 647). Demographics, clinical features, and treatment characteristics were collected and stratified by skin severity and joint activity. Change in joint and skin from enrollment to the 12-month visit was classified by change in category of Clinical Disease Activity Index (CDAI) or body surface area (BSA). Tests of association evaluated the relationship between changes in therapy and changes in skin severity and joint activity. Results. Patients with improvement in both joint activity and skin severity saw the largest median reduction in both CDAI and BSA, while those who worsened in both had the greatest median increase in both CDAI and BSA. The majority of PsA patients (> 50%) had no change in skin severity regardless if they had reduced therapy (50%), no therapy changes (54%), or increased therapy (56%; P = 0.5875). However, there was a significant association between changes in therapy and changes in joint activity (P < 0.001). Patients who increased therapy were more likely to have improvement in joint activity (32%) compared to patients who reduced therapy (22%) or had no therapy changes (11%). Conclusion. The clinical implication for our findings suggests the assessment and incorporation of both skin and joint components may be advisable.

Original languageEnglish (US)
Pages (from-to)376-384
Number of pages9
JournalJournal of Rheumatology
Volume48
Issue number3
DOIs
StatePublished - Mar 1 2021
Externally publishedYes

Keywords

  • Joint
  • Key Indexing Terms: DMARD
  • Patient-reported outcome measures
  • Psoriasis
  • Psoriatic arthritis
  • Skin

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology

Fingerprint

Dive into the research topics of 'Evaluation of changes in skin and joint outcomes and associated treatment changes in psoriatic arthritis (PsA): Experience from the corrona PsA/SpA registry'. Together they form a unique fingerprint.

Cite this